Opioid Antagonist in the Treatment of Ischemic Stroke
| Autor: | Urvish K Patel, Claudio Cruz, Amrapali Patel, Samir Ruxmohan, Taras Halan, Ahmed Eissa-Garcés, Abbas Altamimi, Ivan Mateo Alzamora, Juan Fernando Ortiz, Mahika Khurana |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Neurosciences. Biological psychiatry. Neuropsychiatry Neuroprotection 03 medical and health sciences 0302 clinical medicine Internal medicine Naloxone medicine Stroke Nalmefene Cause of death clinical trials naloxone business.industry General Neuroscience medicine.disease stroke anti-opioids Clinical trial nalmefene 030220 oncology & carcinogenesis Ischemic stroke Systematic Review business 030217 neurology & neurosurgery Opioid antagonist RC321-571 medicine.drug |
| Zdroj: | Brain Sciences Brain Sciences, Vol 11, Iss 805, p 805 (2021) |
| ISSN: | 2076-3425 |
| Popis: | Stroke is a leading cause of death and disability, and novel treatments need to be found, particularly drugs with neuroprotective and restorative effects. Lately, there has been an increased interest in the relationship between opioids and ischemic stroke. To further appreciate this association between opioids and stroke, we conducted a systematic review to investigate anti-opioid medication’s effectiveness in treating ischemic stroke. We used PubMed advanced-strategy and Google Scholar searches and only included full-text clinical trials on humans and written in the English language. After applying the inclusion/exclusion criteria, seven clinical trials were reviewed. Only one of the naloxone and nalmefene clinical trials showed statistically favorable results. Overall, the nalmefene clinical trials used more updated measures (NIHSS, GOS) to evaluate recovery and functional status in ischemic stroke patients than the naloxone clinical trials. There was less bias in the nalmefene clinical trials. Animal and in vitro studies have showed promising results. Additional research should be conducted with new clinical trials of both drugs with larger samples in patients less than 70 years old and moderate to severe infarcts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|